Skip to main content
SpringerLink
Log in

Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism

  • Pharmacokinetics and Disposition
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

To clarify the involvement of cytochrome P450 (CYP) 3A4 in the metabolism of etizolam.

Methods

The effects of itraconazole, a potent and specific inhibitor of CYP3A4, on the single oral dose pharmacokinetics and pharmacodynamics of etizolam were examined. Twelve healthy male volunteers received itraconazole (200 mg/day) or placebo for 7 days in a double-blind randomized crossover manner, and on the 6th day they received a single oral 1-mg dose of etizolam. Blood samplings and evaluation of psychomotor function using the Digit Symbol Substitution Test and Stanford Sleepiness Scale were conducted up to 24 h after etizolam dosing. Plasma concentration of etizolam was measured by means of high-performance liquid chromatography.

Results

Itraconazole treatment significantly increased the total area under the plasma concentration–time curve (AUC; 213±106 ng⁃h/ml versus 326±166 ng⁃h/ml, P<0.001) and the elimination half-life (12.0±5.4 h versus 17.3±7.4 h, P<0.01) of etizolam. The 90% confidence interval of the itraconazole/placebo ratio of the total AUC was 1.38–1.68, indicating a significant effect of itraconazole. No significant change was induced by itraconazole in the two pharmacodynamic parameters.

Conclusion

The present study suggests that itraconazole inhibits the metabolism of etizolam, providing evidence that CYP3A4 is at least partly involved in etizolam metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ahonen J, Olkkola KT, Neuvonen PJ (1995) Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 40:270–272

    CAS  PubMed  Google Scholar 

  2. Andersson T, Miners JO, Veronese ME, Birkett DJ (1994) Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 38:131–137

    CAS  PubMed  Google Scholar 

  3. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquine, hydroxylation phenotype. Clin Pharmacol Ther 45:348–355

    CAS  PubMed  Google Scholar 

  4. Casacchia M, Bolino F, Ecari U (1990) Etizolam in the treatment of generalized anxiety disorder: a double-blind study versus placebo. Curr Med Res Opin 12:215–223

    CAS  PubMed  Google Scholar 

  5. Furukori H, Otani K, Yasui N, Kondo T, Kaneko S, Shimoyama R, Ohkubo T, Nagasaki T, Sugawara K (1998) Effect of carbamazepine on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Neuropsychopharmacology 18:364–369

    Article  CAS  PubMed  Google Scholar 

  6. Garzone PD, Kroboth PD (1989) Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 16:337–364

    CAS  PubMed  Google Scholar 

  7. Gorski JC, Jones DR, Hamman MA, Wrighton SA, Hall SD (1999) Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica 29:931–944

    Article  CAS  PubMed  Google Scholar 

  8. Greenblatt DJ, Wright CE (1993) Clinical pharmacokinetics of alprazolam: therapeutic implications. Clin Pharmacokinet 24:453–471

    CAS  PubMed  Google Scholar 

  9. Hikida K, Inoue Y, Nouchi E, Ohkura Y (1990) Determination of etizolam in human serum or plasma using automated column-switching high-performance liquid chromatography. Jpn J Clin Chem 19:354–359

    CAS  Google Scholar 

  10. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC (1973) Quantification of sleepiness: a new approach. Psychophysiology 10:431–436

    CAS  PubMed  Google Scholar 

  11. Kaplan SA, Jack ML, Alexander K, Weinfeld RE (1973) Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administration. J Pharm Sci 62:1789–1796

    CAS  PubMed  Google Scholar 

  12. Kato K, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Kanno M, Otani K (2003) Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug. Ther Drug Monit 25:473–477

    Article  CAS  PubMed  Google Scholar 

  13. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450 IIIA4. Mol Pharmacol 36:89–96

    CAS  PubMed  Google Scholar 

  14. Luurila H, Olkkola KT, Neuvonen PJ (1996) Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam. Pharmacol Toxicol 78:117–122

    CAS  PubMed  Google Scholar 

  15. Mitsubishi Pharma (2003) Unpublished data in package insert.

  16. Olkkola KT, Beckman JT, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481–485

    CAS  PubMed  Google Scholar 

  17. Otani K, Yasui N, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Hayashi K, Chiba K, Ishizaki T (1997) Effects of genetically determined S-mephenytoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam. Neuropsychopharmacology 16:8-14

    Article  CAS  PubMed  Google Scholar 

  18. Otsuji Y, Okuyama N, Aoshima T, Fukasawa T, Kato K, Gerstenberg G, Miura M, Ohkubo T, Sugawara K, Otani K (2002) No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam. Ther Drug Monit 24:375–378

    Article  CAS  PubMed  Google Scholar 

  19. Savoldi F, Somenzini G, Ecari U (1990) Etizolam versus placebo in the treatment of panic disorder with agoraphobia: a double-blind study. Curr Med Res Opi 12:185–190

    CAS  Google Scholar 

  20. Steinijans VW, Hartmann M, Huber R, Radtke HW (1991) Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 29:323–328

    CAS  PubMed  Google Scholar 

  21. Tsumagari T, Nakajima A, Fukuda T, Shuto S, Kenjo T, Morimoto Y, Takigawa Y (1978) Pharmacological properties of 6-(o-chrorophenyl)-8-ethyl-1-methyl-4H-s-triazolo[3,4-c]thieno[2,3-e] [1,4]diazepine (Y-7131), a new anti-anxiety drug. Arzneimittelforschung 28:1158–1178

    CAS  PubMed  Google Scholar 

  22. Varhe A, Olkkola KT, Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56:601–607

    CAS  PubMed  Google Scholar 

  23. Venkatakrishnan K, von Moltke LL, Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism. Clin Pharmacokinet 38:111–180

    CAS  PubMed  Google Scholar 

  24. Wechsler D (1981) Wechsler adult intelligence scale, revised. Harcourt Brace Jovanovich, New York

  25. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Chiba K, Ishizaki T (1996) A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 59:514–519

    CAS  PubMed  Google Scholar 

  26. Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K (1998) Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology 139:269–273

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuropsychiatry, Yamagata University School of Medicine, 990-9585, Yamagata , Japan

    K. Araki, T. Fukasawa, T. Aoshima, A. Suzuki & K. Otani

  2. Department of Clinical Pharmacology, Hirosaki University School of Medicine, Hirosaki, Japan

    N. Yasui-Furukori & T. Tateishi

  3. Pharmaceutical Research Division, Mitsubishi Pharma, Fukuoka, Japan

    Y. Inoue

Authors
  1. K. Araki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Yasui-Furukori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Fukasawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Aoshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y. Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Tateishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. Otani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Fukasawa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Araki, K., Yasui-Furukori, N., Fukasawa, T. et al. Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol 60, 427–430 (2004). https://doi.org/10.1007/s00228-004-0789-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-004-0789-1

Keywords

Search

Navigation